Advertisement
UK markets close in 8 hours 11 minutes
  • FTSE 100

    8,068.18
    +27.80 (+0.35%)
     
  • FTSE 250

    19,620.81
    -98.56 (-0.50%)
     
  • AIM

    754.95
    +0.26 (+0.03%)
     
  • GBP/EUR

    1.1660
    +0.0015 (+0.13%)
     
  • GBP/USD

    1.2493
    +0.0031 (+0.24%)
     
  • Bitcoin GBP

    51,525.16
    -1,972.62 (-3.69%)
     
  • CMC Crypto 200

    1,390.77
    +8.19 (+0.59%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CRUDE OIL

    83.05
    +0.24 (+0.29%)
     
  • GOLD FUTURES

    2,333.50
    -4.90 (-0.21%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,293.61
    +92.34 (+0.54%)
     
  • DAX

    18,035.82
    -52.88 (-0.29%)
     
  • CAC 40

    8,094.28
    +2.42 (+0.03%)
     

What's in Store for Capitala Finance (CPTA) in Q2 Earnings?

Capitala Finance Corp. CPTA is scheduled to announce second-quarter 2019 results on Aug 5, after the market closes. Its revenues and earnings are projected to grow year over year.

In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate. Its results benefited from rise in total investment income, partly offset by higher expenses.

The company does not have an impressive earnings surprise history. Its earnings surpassed the Zacks Consensus Estimate in only one of the trailing four quarters.

Capitala Finance Corp. Price and EPS Surprise

Capitala Finance Corp. Price and EPS Surprise
Capitala Finance Corp. Price and EPS Surprise

Capitala Finance Corp. price-eps-surprise | Capitala Finance Corp. Quote

ADVERTISEMENT

Moreover, activities of the company in the second quarter failed to win analysts’ confidence. As a result, the Zacks Consensus Estimate for earnings of 25 cents has remained unchanged over the past 30 days. Nonetheless, it implies 13.6% growth from the year-ago quarter’s reported figure.

Further, the consensus estimate for sales of $12.48 million suggests growth of 5.1% on a year-over-year basis.

Before we take a look at what our quantitative model predicts for the to-be-reported quarter, let’s check the factors that are likely to impact results.

Factors to Impact Q2 Results

Given the contraction in LIBOR rates in the second quarter, Capitala Finance’s floating-rate debt investments, which are tied to LIBOR will likely hurt investment income. Nevertheless, the expectation of higher prepayment activity during the quarter is likely to have supported total investment income to some extent.

Earnings Whispers

According to our quantitative model, it cannot be conclusively predicted whether Capitala Finance will be able to beat the Zacks Consensus Estimate this time. This is because it does not have the right combination of the two key ingredients — a positive Earnings ESP and Zacks Rank #3 (Hold) or higher — for increasing the odds of an earnings beat.

You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Earnings ESP: Capitala Finance has an Earnings ESP of 0.00%.

Zacks Rank: The company currently carries a Zacks Rank #3. While this increases the predictive power of ESP, we also need a positive ESP to be confident of an earnings beat.

Stocks That Warrant a Look

Here are a few stocks that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases:

Apollo Investment Corporation AINV is scheduled to release results on Aug 6. It presently has an Earnings ESP of +1.82% and a Zacks Rank #3.

Banco Macro S.A. BMA is expected to release results on Aug 28. It has an Earnings ESP of +11.83% and a Zacks Rank #3.

Eaton Vance Corporation EV is expected to release quarterly results on Sep 4. It has an Earnings ESP of +3.21% and currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Macro Bank Inc. (BMA) : Free Stock Analysis Report
 
Eaton Vance Corporation (EV) : Free Stock Analysis Report
 
Apollo Investment Corporation (AINV) : Free Stock Analysis Report
 
Capitala Finance Corp. (CPTA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research